NephroSant has announced that the Journal of Clinical Medicine has published real-world data that provides insight into how changes in allograft health are reflected in specific ranges of QSant scores. QSant is a non-invasive home collection that analyses biomarkers of kidney transplant rejection in urine and provides a score from 0–100 that can inform treatment decisions.
Results from this real-world data study of 235 adults and children who received kidney transplants at 11 US transplant centres show that QSant scores of <32 indicate stable immune quiescence, according to NephroSant. “Importantly, not only does a score of less than 32 indicate the health of a patient’s kidney transplant, but it may negate the need for invasive biopsies,” a press release states.
The study results identified a QSant score of between 32 and 55 to indicate a state of alloimmunity flux. A decreasing gradient in this range may indicate a resolution of rejection following successful immunomodulation. In contrast, patients with an increasing gradient between 32 and 55 may be advancing towards an allograft rejection event. Lastly, a QSant score of more than 55 indicates histologically concordant acute rejection, the release adds.
The open-access article, titled “Through the looking glass: Unravelling the stage-shift of acute rejection in renal allografts”, was published online in February 2022.
“We developed QSant to aid physicians in the early detection of rejection in order to protect patients from an untimely loss of a transplanted kidney,” said NephroSant founder Minnie Sarwal. “Results from this real-world data study provide important insights for physicians when interpreting QSant scores. By understanding how these scores relate to a patient’s rejection risk, physicians can assess their patients’ evolving needs for immunomodulation throughout the continuum of their post-transplant care.”